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Effect of 1% sodium alendronate 
in the non-surgical treatment of 
periodontal intraosseous defects: a 
6-month clinical trial
Background and objectives: Few studies have evaluated the effect of 
the topical application of sodium alendronate (ALN) on the treatment of 
intrabuccal bone defects, especially those caused by periodontitis. This 
6-month randomized placebo controlled clinical trial aimed at evaluating 
the effect of non-surgical periodontal treatment associated with the use of 
1% ALN, through clinical evaluations and cone-beam computed tomography 
(CBCT). Material and Methods: Twenty individuals with chronic periodontitis 
underwent periodontal examination at the baseline as well as 3 and 6 months 
after periodontal treatment, registering clinical attachment level (CAL), 
periodontal probing depth (PPD), and bleeding on probing (BOP) as the 
clinical outcomes. After manual scaling and root planing, 40 bilateral sites 
with interproximal vertical bone defects were randomly treated with either 
1% ALN gel or a placebo. Bone defects were evaluated through CBCT at the 
baseline and 6 months post-treatment. The clinical and CBCT parameters 
???????????????????????????????????????????????????????????????????????
Although ALN produced a greater CAL gain when compared to the placebo 
at 6 months post-treatment (p=0.021), both treatments produced similar 
?????????????????????????????????????????????????????????????????????????????
were observed only in patients of the ALN group (4.5 to 3.8 mm; p=0.003) at 
6 months post-treatment. Conclusions: Topical application of 1% ALN might 
????????????????????????????????????????????????????????????
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Introduction
??????????????????????????????????????????????????
the gingiva extending into the adjacent attachment 
apparatus3. The disease is characterized by loss of 
clinical attachment due to the destruction of the 
periodontal ligament and of the adjacent supporting 
bone. It is highly prevalent among adult populations1. 
Because of the previously demonstrated capacity 
of the periodontal tissues for regeneration8, there 
has been increased interest in the mechanisms of 
periodontal wound healing and the biological factors 
and cells involved in this process13. A wide range 
of regenerative techniques has been proposed 
along the years, many of those involving bone 
grafts or their synthetic substitutes13, guided tissue 
regeneration21, topical application of growth factors22, 
stem cells11, antiresorptive agents27, or combinations of 
procedures13,22. However, some of these regenerative 
techniques have restricted predictability, high cost, 
???? ?????????? ????????????? ??????????? ???? ????????? ???
bioactive molecules using vehicles known as carrier 
agents has an important role in tissue regenerative 
therapy7.
Biphosphonates (BPhs) are a group of bone 
metabolism mediators, presently used to treat 
osteoclast-mediated bone loss due to osteoporosis 
and other conditions5,9. Due to their effects on the 
differentiation, activity, and apoptosis of osteoclasts, 
they slow down the rate of bone loss and increase 
the resistance to bone fracture19. Sodium alendronate 
(ALN), an aminobisphosphonate, acts as a potent 
inhibitor of bone resorption4,10??????????????????????????
of ALN for hydroxyapatite, it has been suggested 
that the ALN drug complex is retained at the site 
of injection12,16. In vitro studies demonstrated that 
low-dose ALN was effective in inhibiting osteoclastic 
activity with no cytotoxic effects20, as well as effect 
on regulatory genes of osteoblasts differentiation2,10,14. 
Therefore, some studies have been conducted to 
????????? ???? ???????? ??? ???? ??? ???? ?????????? ???
bone and periodontal disorders26-28,33. Animal studies 
have evaluated the effects of both the topical6,10,16 
and systemic15,17,32 use of ALN in the treatment of 
intrabuccal bone defects resulting from periodontitis. 
In humans, clinical trials have investigated the effects 
of the topical application of ALN on periodontal 
bone defects treated with surgical27 or non-surgical 
procedures17,26,28,29. It is important to note that no 
adverse effects were reported in any study on the 
topical application of ALN26,28,29.
While the majority of the studies were designed to 
evaluate the effects of 1% ALN gel on bone parameters, 
only few studies focused on its effects on periodontal 
clinical parameter25. Although improvements in 
periodontal probing depth (PPD), clinical attachment 
level (CAL), bleeding on probing (BOP), and gingival 
index (GI) resulting from the use of ALN have 
already been reported17,26-29, the available data is still 
controversial. Therefore, further studies are required 
for a better understanding on how ALN affects 
periodontal healing in periodontitis patients.
Based on the hypothesis that the adjunctive 
use of ALN would improve periodontal status, this 
6-month randomized placebo controlled clinical trial 
evaluated the effect of scaling and root planing in 
combination with the topical application of 1% ALN 
gel on periodontal clinical parameters and cone-beam 
computed tomography (CBCT) measurements.
Material and methods
Study population
?????????????????????????????????????????????????
with the purpose of training and adjusting study 
protocols. Data from this pilot study was not included 
???????????????????????????????????????????????????????
randomized, split-mouth, placebo-controlled clinical 
trial comprised patients looking for dental treatment 
between November 2012 and November 2013 (Figure 
1). This study was approved by the Institutional Ethics 
Committee (protocol #22493714.5.0000.5149) and 
registered at Clinicaltrials.gov (NTC02470611).
The inclusion criteria were: a) moderate/advanced 
chronic periodontitis3, b) age between 35 and 60 
years old, and c) presence of two contralateral 
teeth, featuring contact with the adjacent teeth, with 
????? ???????????????????????? ????????????? ???
associated with proximal vertical bone defects, without 
furcation lesions, premature occlusal contact, or 
prostheses. In addition, these two contralateral teeth 
should have the same number of roots and be located 
on the same dental arch with ??? ? difference in their 
PPD baseline values.
The exclusion criteria were: a) antibiotics use or 
any other medication that could interfere in the results, 
b) periodontal treatment within the six months prior to 
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the study, c) pregnancy or breastfeeding, d) depressed 
immune systems, e) diabetes or any other medical 
comorbidity that could impact on the general health, f) 
smoking, g) orthodontic appliances and/or removable 
prostheses, h) medical history of osteoporosis, and i) 
allergy to BPHs or history of their systemic use.
The sample size was calculated based on the 
primary outcome of the study, i.e., changes in CAL 
measurements. The mean and standard deviation 
values of CAL gain from the previous studies28,29 were 
???????????????????????????????????????????????????????
80% power, and 25% difference between the studied 
groups, a minimum sample of 15 sites per group was 
determined to be necessary. Considering a loss of 
up to 30%, previously reported in similar studies, a 
sample number of 20 sites per?????????????????????
appropriate. Therefore, trough a split-mouth design, 20 
individuals who met the inclusion and exclusion criteria 
were enrolled and ???? ????? ??????????? ?????????
of 40 sample units: 20 sites allocated to 1% ALN 
gel application and 20 sites allocated to placebo gel 
application. 
Periodontal examination
The full-mouth PPD, CAL, BOP, and plaque index30 
were evaluated at 4 sites per tooth (distal, mesial, 
buccal, and lingual) using a manual periodontal probe 
(PCPUNC-15, Hu-Friedy, Chicago, IL) at the baseline 
and 3- and 6-month follow-ups after treatment, by 
a single calibrated periodontist (P.A.D.O). The kappa 
values for the intra-examiner agreement of the PPD 
and CAL measurements at the baseline and 3- and 
6-months follow-ups were >0.82.
Radiographic and CBCT examination
At the baseline, the Kodak 2200 Intraoral X-Ray 
System X-ray machine (Eastman Kodak Company, 
Rochester, NY, USA) was used to acquire periapical 
radiographs of the teeth for diagnostic purposes. The 
Scan-X Duo system (Air Techniques, Melville, NY, 
USA) was used for digital photostimulable phosphor 
Figure 1- ?????????????????????
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imaging. The radiographs were acquired following the 
paralleling technique by a single operator, using the 
Rinn (Dentisply, USA) positioning sensor model. The 
????? ????????????????????????? ?????????????????????
to the criteria adopted by Nibali, et al.24 (2011). 
?????????????????????????????? ?????????????????
at 6 months post-treatment using standardized 
tomographic images acquired through CBCT using 
the Kodak 9000 3D CBCT (Eastman Kodak Company, 
Rochester, NY, USA), operating at 60 kV and 10 
mA, with an exposure time of 10.8 s, scanning at a 
collimation of 5.0 cm x 3.7 cm, and an isotropic voxel 
??????????????????????????????
Two trained, blinded, and calibrated specialists 
(A.M.S.D.O and F.R.M) independently analyzed all 
tomographic images. The intra and inter-examiner 
??????????????????????????????????????? ?????????????
?????????????????? ???? ???????????? ???????????? ?????
showed scores higher than 0.95. The tomographic 
images were measured directly using the Kodak 
Dental Imaging Software KDIS (Kodak Dental 
Systems, Rochester, NY, USA) on a computer with a 
GeForce 9500 GT graphics card, an LED monitor with 
1920x1080 pixel resolution, and default brightness 
and contrast levels.
The electronic measuring tool included in the 
CBCT software allowed measurements to the nearest 
hundredth of a millimetre. The cross-sectional 
slice thickness was reconstructed to 1 mm for all 
measurements, and the location of each slice was 
??????????????????????????????????????????????????????
of the measurements were performed using only 
one computer, with unaltered screen settings. The 
examiners were allowed to modify bone density and 
image size to enable optimal viewing. The distance 
between the cement-enamel junction and the deepest 
point of the bone defect was used as the reference 
parameter for the analyzed measurements, as 
proposed by Misch, Yi and Sarment21 (2006).
Non-surgical periodontal therapy
After the baseline clinical and CBCT examinations, 
the individuals were provided with oral hygiene 
instructions and dental prophylaxis. Quadrant-wise 
supra and subgingival debridement were performed in 
weekly sessions by a trained and blinded periodontist 
(B.C.D). Scaling and root planing were performed 
under local anaesthesia using Gracey and McCall 
manual curettes (Hu-Friedy, Chicago, IL, USA). 
The curettes were sharpened before each use and 
discarded after six consecutive uses. For each 
individual included in the study, the sites selected for 
the subgingival application of either 1% ALN or placebo 
gel were scaled in the last session of the periodontal 
treatment. After scaling, the experimental periodontal 
sites were randomly assigned to receive either 1% ALN 
gel (Injecta Center, Ribeirão Preto, São Paulo, Brasil), 
according to the formulation proposed by Reddy, 
Kumar and Veena27 (2005), or a sterile placebo (same 
chemical composition without addition of ALN) gel 
(Injecta Center, Ribeirão Preto, São Paulo, Brasil), by 
a blinded researcher (B.C.D). To maintain the patients’ 
and researchers’ blinding, the ALN and placebo gels 
were dispensed in identical syringes labelled as gel A 
or gel B, without any additional information except 
expiration date.
??????????????? ??? ????????????????? ????????????
prescribed after periodontal treatment. Additional 
oral hygiene instructions and oral prophylaxis were 
periodically administered (15, 30, and 60 days after 
intervention). Any adverse effects were recorded at 
the recall visits.
Statistical analysis
Periodontal clinical parameters were compared over 
time using the Friedman test. The Wilcoxon test was 
used to evaluate both the effects of each treatment 
on the CBCT measurements and the inter-group 
differences. The statistical analyses were performed 
using the statistical software SPSS (SPSS, Chicago, 
IL, USA) version 14.0 for Windows. Results were 
?????????????????????????????????????????????????????
(p????????
Results
The present study included 20 participants (mean 
age 44.9 years old), the majority of whom were female 
(60%), whose proximal contralateral sites (n=40) 
were analyzed. The majority of the sites selected 
for the topical application of either 1% ALN gel or a 
placebo gel were located on the lower posterior teeth 
(90%) (Table 1).
The periodontal treatment produced improvements 
in the clinical parameters of the participants (Table 
2). The percentages of both BOP and PPD (4–6 mm 
??????????????????????????????????????????????????
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Parameters Groups Experimental times p-value
Periodontal 
Probing Depth 
??????????????
(n=20 sites)
Baseline 3 months 6 months 
ALN 6.4±1.4 4.3±1.6 4.3±1.6 < 0.001
[Baseline > (3 months = 6 months)]
Placebo 6.2±1.6 4.4±1.8 4.4±1.7 0.004
[Baseline > (3 months = 6 months)]
p-value 0.468
(ALN = Placebo)
0.239
(ALN = Placebo)
0.127
(ALN = Placebo)
Clinical 
attachment level 
?????????????
(n=20 sites)
ALN 6.9±1.2 4.3±1.1 3.6±0.7 < 0.001
(Baseline > 3 months > 6 months)
Placebo 6.7±1.1 5.1±0.9 4.3±0.7 < 0.001
(Baseline > 3 months > 6 months)
p-value 0.356
(ALN = Placebo)
0.010
(ALN = Placebo)
0.021
(ALN = Placebo)
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????? ??????????? ?????????????????????????????????????????????????????????????????????????????????????
Table 3- Comparison of the mean periodontal probing depth (mm) and clinical attachment level (mm) according to the treatment groups 
(1% ALN gel or placebo gel) over time
Variables N %
Age (mean±SD) 44.9±7.9
Gender Female
Male
12
8
60.00%
40.00%
Education level < 8 years
8 to 12 years
> 12 years
5
11
4
25.00%
55.00%
20.00%
Arch Mandible
Maxilla
36 4 90.00%
10.00%
Segment of the arch Anterior
Posterior
4
36
10.00%
90.00%
Table 1- Characterization of the sample according to the demographic variables and analyzed teeth (n=20 individuals)
Parameters Experimental times P-value
Baseline 3 months 6 months
Plaque index 
(mean±sd)
42.5±14.6 28.2±14.4 23.0±8.4 < 0.001
[Baseline > (3 months = 6 months)]
BOP 
(mean±sd)
34.5±25.0 16.7±11.7 14.5±9.8 0.003
(Baseline > 3 months > 6 months)
PPD (mm)
(mean±sd)
3.2±0.7 2.5±0.6 2.3±0.8 < 0.001
(Baseline > 3 months > 6 months)
CAL mm 
(mean±sd)
2.6±0.9 2.1±0.9 2.1±0.9 0.001
[Baseline > (3 months = 6 months)]
% sites with
PPD <4 mm
64.8±15.5 81.4±12.7 86.2±10.8 < 0.001
[Baseline < (3 months = 6 months)]
% sites with 
PPD between
4 and 6 mm
28.0±13.5 16.8±11.6 11.7±8.4 < 0.001
(Baseline > 3 months > 6 months)
% sites with 7.2±4.7 1.7±2.2 2.1±3.2 < 0.001
PPD >6 mm [Baseline > (3 months = 6 months)]
% sites with 
CAL >3 mm
42.2±1.4 28.0±21.2 28.2±18.0 < 0.001
[Baseline > (3 months = 6 months)]
Table 2-??????????????????????????????????????????????????? ???????????????????????????????????????????????????
????????????????????????????????????????????????????? ??????????????????????????????????????????? ?????????? ??????????????????????????
????????????????????????????????????????????????????????????????????????
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periodontal treatment. On the other hand, a gain in 
CAL and an increase in the percentage of sites with 
???????????????????????????????????? ???
Table 3 shows the comparative results of the 
primary outcome (CAL measurement) of the two 
treatment groups (1% ALN and placebo gels). 
Although the PPD reductions in both treatments at the 
6-month follow-up were similar, ALN application after 
scaling produced a greater CAL gain at the 3-month 
follow-up. This difference was also observed at the 
6-month follow-up.
Bone measurements are shown in Table 4. The 
intra-group analysis ????????? ??????????? ??????????? 
in the CBCT-based measurements only in the 1% 
ALN group (baseline, 4.5 mm; 6 months, 3.8 mm; 
p????????????????????????????????????????????????????
no differences between the mean measurements of 
the ALN and placebo gel-treatment groups (p=0.112).
Both therapies were well tolerated by the 
participants. No periodontal abscesses occurred during 
the course of the study. Only one case of periapical 
abscess was observed; but the abscess was not in an 
experimental site and its treatment did not require 
antibiotics. None of the adverse effects was considered 
to be related to the investigational gel.
Discussion
Few studies have focused on the topical application 
of ALN in humans17,26-29. Despite the differences in 
methodology, these studies25-28 reported positive effects 
of ALN application in comparison to the placebo, which 
was evident from the reduction in PPD, gain in CAL, 
????????????????????????????????????????????????????????
??????????????????????????????????????????????????????
root planing in the treatment of infrabony defects 
was demonstrated even in patients with chronic25 and 
aggressive29 periodontitis. Therefore, the present study 
?????????????????????????????????????????????????????
adjuvant in the treatment of chronic periodontitis. Since 
CAL is considered the clinical gold standard outcome in 
clinical periodontology, it was selected as the primary 
???????????????????????????????????????????????????
present study corroborate with the previously reported 
???????????????????????17,28,29. Additionally, the results 
????????? ???? ???????? ??? ????????????????????????
procedures in the treatment of periodontitis. 
In the present study, only the ALN group showed 
?????????? ?????????????? defects, revealed by a decrease 
in bone height. Although ALN has been previously 
??????????????? ?????????????????????????????????????????
in the present study ??????????????????????? difference 
in comparison to the placebo. ?? ??????????????????????
of a previous study31, ??????????????????????????????????
extraction sockets despite causing an enhancement 
in bone formation. However, we are not sure whether 
????????????????????????????????????????????????????????
follow-up longer than 6 months. This limitation could 
be addressed in future studies. On the other hand, a 
positive aspect of the present study is the larger sample 
size compared with previous studies27,30, although study 
power was not higher than 80%. However, external 
validity is still a barrier to be overcome. 
Additionally, it should be emphasized that ALN did 
not cause any local adverse events. This fact reinforces 
the advantages of its topical application over its 
systemic use, thus contributing to greater safety and 
better conformance of the individuals. 
In the present study, the measurement of the 
interproximal bone defects was performed using the 
CBCT images acquired at the baseline and at 6 months 
??????????????????????????????????????????????????????
mean bone height was observed in sites that received 
Groups Experimental times p-value
Baseline (mm) 6 months (mm)
ALN
(n=20 sites)
4.5±1.8 3.8±2.0 0.003 
(Baseline > 6 months)
Placebo 
(n=20 sites)
5.1±2.2 4.9±2.0 0.099
(Baseline = 6 months)
p-value 0.470 
(ALN = Placebo)
0.112 
(ALN = Placebo)
????? ????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????????????
????????????????????????????????????????????????????????? ???????? ??????????????????????????????????????????????
Table 4-?????????????????????????????????????????????????????????????????????????????? ?
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1% ALN gel, while the measurements of the sites 
treated with the placebo as with the adjunctive gel 
were unchanged. Some studies27-29 have also reported 
?????????????????????????????????????????????????????????
the ALN gel. Interestingly, previous studies have used 
periapical radiographs, which have lower sensitivity 
than CBCT21. It is also relevant to mention that the 
? ??????????? ?????????? ??? ???? ???????? ???????????
associated with conservative procedures. Further 
studies are required to establish the pattern of 
clinical and tomographic outcomes exhibited upon the 
application of ALN in the surgical treatment of chronic 
periodontitis.
It is important to reinforce that a great debate 
exist regarding the use of systemic bisphosphonates 
and the incidence of osteonecrosis associated with 
surgical procedures in the oral cavity. There is some 
evidence suggesting that osteonecrosis can occur in 
individuals on long-term high potency bisphosphonates 
used via the intravenous route of administration16. 
Unfortunately, osteonecrosis of the jaw has been 
reported as an adverse event associated with the 
long-term or systemic use of BPhs5. The prevalence of 
this adverse event has been reported to be 0.5% and 
1.8% in patients undergoing cancer treatment and on 
long-term intravenous medication, respectively; on the 
other hand, an average of 4.4 years of systemic use 
of BPhs in the treatment of osteopenia/osteoporosis 
resulted in osteonecrosis in a fewer number of patients 
(0.2%)18. For reasons not yet completely understood, 
oral osteonecrosis seems to have a few risk factors 
such as the changes in the patterns of bone resorption 
and remodeling, decrease in angiogenesis due to 
reduction in growth, migration and differentiation of 
???????????????????????????????????????????????????
infection4,18.
Corroborating with our results, studies using 
low-dose topical ALN administration did not present 
adverse effects17,26,27. Nevertheless, caution should be 
exercised when considering the results of the present 
study in the clinical environment since future studies 
should be conducted on the potential cumulative 
effects of topical ALN administration.
????????????????????? ????????????????????????????
adjuvant in providing greater gain in CAL, although its 
???????????? ??????? ??? ??????????? ?????????????????
compared to the placebo in terms of the reduction 
of PPD and bone fill. In this sense, the present 
study can be considered a good starting point for 
future studies directed towards providing additional 
information on topical ALN use in periodontal therapy.
Conclusions
The present study demonstrated that the topical 
application of 1% ALN improved the periodontal 
clinical status and might be ??????????? adjuvant to 
non-surgical periodontal therapy.
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